GlassScriptPhysician profile
Robin Allen Baker
NPI 1881699718
$4,425.17
in general payments reported to CMS, 2019-2025
33 companies · $515 in 2025
The $515 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,369 · 2020: $1,208 · 2021: $783 · 2022: $237 · 2023: $179 · 2024: $134 · 2025: $515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $828.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $827.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $634.29 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $470.36 | 2019-2025 | Airsupra |
| Amgen INC. | $413.52 | 2019-2025 | Evenity, Prolia, Repatha |
| Pfizer INC. | $410.24 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $286.58 | 2019-2021 | |
| Lilly USA, LLC | $260.78 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Merck Sharp & Dohme LLC | $229.98 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $216.90 | 2019-2025 | |
| Astellas Pharma US INC | $202.23 | 2019-2021 | |
| Esperion Therapeutics, INC. | $146.90 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $126.00 | 2019-2021 | |
| Mylan Specialty L.P. | $113.24 | 2019-2021 | |
| Glaxosmithkline, LLC. | $102.97 | 2020-2025 | Shingrix, Arexvy |
| Amarin Pharma, INC. | $74.63 | 2019-2020 | |
| Dexcom, INC. | $71.10 | 2020-2025 | Dexcom G6 Transmitter |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $69.62 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.47 | 2019-2025 | Xifaxan |
| Exact Sciences Corporation | $68.36 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Abbott Laboratories | $59.81 | 2020-2023 | Freestyle Libre 3 |
| Abbvie INC. | $58.11 | 2021-2022 | |
| Allergan, INC. | $56.82 | 2019-2020 | |
| Boston Scientific Corporation | $52.04 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $47.42 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.04 | 2025 | |
| Jazz Pharmaceuticals INC. | $28.61 | 2021 | |
| Dynavax Technologies Corporation | $23.65 | 2025 | Heplisav-B |
| Insulet Corporation | $17.61 | 2025 | Omnipod |
| Kowa Pharmaceuticals America, INC. | $16.36 | 2019 | |
| Currax Pharmaceuticals LLC | $14.75 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.94 | 2022 | |
| Nalpropion Pharmaceuticals LLC | $13.40 | 2019 | |
| Mannkind Corporation | $11.87 | 2019 | |
| Nabriva Therapeutics, Plc | $11.57 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.